Apyx Medical (APYX) 10-Q 12 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 09, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	0-12183
Entity Registrant Name	APYX MEDICAL CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-2644611
Entity Address, Address Line One	5115 Ulmerton Road,
Entity Address, City or Town	Clearwater
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33760
City Area Code	727
Local Phone Number	384-2323
Title of 12(b) Security	Common Stock
Trading Symbol	APYX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		34,343,750
Entity Central Index Key	0000719135
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 30,898	$ 41,915
Trade accounts receivable, net of allowance of $360 and $300	11,444	8,399
Income tax receivables	7,654	7,654
Other receivables	873	1,275
Inventories, net of provision for obsolescence of $303 and $388	6,040	4,051
Prepaid expenses and other current assets	2,967	2,795
Total current assets	59,876	66,089
Property and equipment, net of accumulated depreciation and amortization of $5,145 and $4,813	6,412	6,541
Operating lease right-of-use assets	152	237
Finance lease right-of-use assets	274	437
Other assets	1,055	807
Total assets	67,769	74,111
Current liabilities:
Accounts payable	3,044	1,511
Accrued expenses and other current liabilities	8,324	7,278
Current portion of operating lease liabilities	125	126
Current portion of finance lease liabilities	218	238
Total current liabilities	11,711	9,153
Long-term operating lease liabilities	30	129
Long-term finance lease liabilities	22	183
Contract liabilities	1,200	621
Other liabilities	146	166
Total liabilities	13,109	10,252
EQUITY
Common stock, $0.001 par value; 75,000,000 shares authorized; 34,339,533 issued and outstanding as of September 30, 2021, and 34,289,222 issued and outstanding as of December 31, 2020	34	34
Additional paid-in capital	64,862	61,066
(Accumulated deficit) retained earnings	(10,548)	2,621
Total stockholders' equity	54,348	63,721
Non-controlling interest	312	138
Total equity	54,660	63,859
Total liabilities and equity	$ 67,769	$ 74,111

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 360	$ 300
Inventories, provision for obsolescence	303	388
Accumulated depreciation and amortization	$ 5,145	$ 4,813
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	34,339,533	34,289,222
Common stock, shares outstanding (in shares)	34,339,533	34,289,222

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Sales	$ 11,831	$ 6,954	$ 31,693	$ 16,247
Cost of sales	3,775	2,229	10,243	6,444
Gross profit	8,056	4,725	21,450	9,803
Other costs and expenses:
Research and development	1,175	1,047	3,374	3,002
Professional services	2,032	1,835	5,442	5,882
Salaries and related costs	4,206	3,508	12,794	10,258
Selling, general and administrative	4,611	2,706	12,596	8,691
Total other costs and expenses	12,024	9,096	34,206	27,833
Loss from operations	(3,968)	(4,371)	(12,756)	(18,030)
Interest income	2	10	9	233
Interest expense	(3)	(25)	(9)	(39)
Other (loss) income, net	(192)	(63)	(188)	349
Total other (loss) income, net	(193)	(78)	(188)	543
Loss before income taxes	(4,161)	(4,449)	(12,944)	(17,487)
Income tax expense (benefit)	73	(715)	246	(7,112)
Net loss	(4,234)	(3,734)	(13,190)	(10,375)
Net loss attributable to non-controlling interest	(12)	(6)	(21)	(6)
Net loss attributable to stockholders	$ (4,222)	$ (3,728)	$ (13,169)	$ (10,369)
Loss per share:
Basic (in dollars per share)	$ (0.12)	$ (0.11)	$ (0.38)	$ (0.30)
Diluted (in dollars per share)	$ (0.12)	$ (0.11)	$ (0.38)	$ (0.30)

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)	Non-controlling Interest
Beginning balance (in shares) at Dec. 31, 2019		34,170
Beginning balance at Dec. 31, 2019	$ 71,259	$ 34	$ 56,708	$ 14,517	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Contributions from non-controlling interest	148				148
Shares issued on stock options exercises for cash (in shares)		20
Shares issued on stock options exercises for cash	97		97
Stock based compensation	3,209		3,209
Shares issued on net settlement of stock options (in shares)		33
Net loss	(10,375)			(10,369)	(6)
Ending balance (in shares) at Sep. 30, 2020		34,223
Ending balance at Sep. 30, 2020	64,338	$ 34	60,014	4,148	142
Beginning balance (in shares) at Jun. 30, 2020		34,202
Beginning balance at Jun. 30, 2020	66,836	$ 34	58,926	7,876	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Contributions from non-controlling interest	148				148
Shares issued on stock options exercises for cash (in shares)		10
Shares issued on stock options exercises for cash	25		25
Stock based compensation	1,063		1,063
Shares issued on net settlement of stock options (in shares)		11
Net loss	(3,734)			(3,728)	(6)
Ending balance (in shares) at Sep. 30, 2020		34,223
Ending balance at Sep. 30, 2020	64,338	$ 34	60,014	4,148	142
Beginning balance (in shares) at Dec. 31, 2020		34,289
Beginning balance at Dec. 31, 2020	63,859	$ 34	61,066	2,621	138
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Contributions from non-controlling interest	195				195
Shares issued on stock options exercises for cash (in shares)		11
Shares issued on stock options exercises for cash	49		49
Stock based compensation	3,747		3,747
Shares issued on net settlement of stock options (in shares)		40
Net loss	(13,190)			(13,169)	(21)
Ending balance (in shares) at Sep. 30, 2021		34,340
Ending balance at Sep. 30, 2021	54,660	$ 34	64,862	(10,548)	312
Beginning balance (in shares) at Jun. 30, 2021		34,323
Beginning balance at Jun. 30, 2021	57,682	$ 34	63,650	(6,326)	324
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued on stock options exercises for cash (in shares)		3
Shares issued on stock options exercises for cash	28		28
Stock based compensation	1,184		1,184
Shares issued on net settlement of stock options (in shares)		14
Net loss	(4,234)			(4,222)	(12)
Ending balance (in shares) at Sep. 30, 2021		34,340
Ending balance at Sep. 30, 2021	$ 54,660	$ 34	$ 64,862	$ (10,548)	$ 312

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities
Net loss	$ (13,190)	$ (10,375)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	674	662
Provision for inventory obsolescence	15	427
Loss on disposal of property and equipment	47	0
Stock based compensation	3,747	3,209
Provision for allowance for doubtful accounts	57	486
Changes in operating assets and liabilities:
Trade receivables	(3,168)	1,389
Prepaid expenses and other assets	(23)	(981)
Income tax receivables	0	(6,812)
Inventories	(1,982)	(717)
Accounts payable	1,555	15
Accrued and other liabilities	1,605	(2,352)
Net cash used in operating activities	(10,663)	(15,049)
Cash flows from investing activities
Purchases of property and equipment	(391)	(193)
Net cash used in investing activities	(391)	(193)
Cash flows from financing activities
Proceeds from stock option exercises	49	97
Repayment of finance lease liabilities	(181)	(184)
Contributions from non-controlling interests	195	148
Net cash provided by financing activities	63	61
Effect of exchange rates on cash	(26)	(92)
Net change in cash and cash equivalents	(11,017)	(15,273)
Cash and cash equivalents, beginning of period	41,915	58,812
Cash and cash equivalents, end of period	30,898	43,539
Cash paid for:
Interest	8	39
Income taxes	$ 13	$ 54

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION A pyx Medical Corporation (“Company", "Apyx", "it" and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760. The Company is an advanced energy technology company with a passion for elevating people’s lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients they serve. It's Helium Plasma Technology is marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma® system allows surgeons to operate with a high level of precision, virtually eliminating unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers. The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic and its impact on the level of economic activity around the world including ongoing supply chain disruptions. The extent of the impact of the pandemic on the Company's business is highly uncertain and difficult to predict, as the responses and information related to it continue to change. As elective surgery cases using the Company’s Helium Plasma Technology have started to increase again, it is unknown whether these trends will continue. The full extent to which the COVID-19 pandemic may materially and adversely impact the Company’s future financial position, liquidity, or results of operations remains uncertain. The accompanying unaudited condensed consolidated financial statements have been prepared based upon SEC rules that permit reduced disclosure for interim periods. For a more complete discussion of significant accounting policies and certain other information, please refer to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of management these condensed consolidated financial statements reflect all adjustments that are necessary for a fair presentation of results of consolidated operations and financial condition for the interim periods shown, including normal recurring accruals and other items. The results for the interim periods are not necessarily indicative of results for the full year. Reclassifications We have reclassified certain amounts presented in the prior period to conform to the current period presentation. These reclassifications had no impact on previously reported net loss, retained earnings or net cash used in operating activities for the periods presented.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2021
Accounting Standards Update and Change in Accounting Principle [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates , which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the condensed consolidated financial statements, we do not expect the impact to be material. No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.

DISPOSAL OF BUSINESS

DISPOSAL OF BUSINESS	9 Months Ended
	Sep. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]
DISPOSAL OF BUSINESS	DISPOSAL OF BUSINESS On August 30, 2018, the Company closed on a definitive asset purchase agreement (the "Asset Purchase Agreement") with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly owned subsidiary of Symmetry Surgical Inc. (“Symmetry”), pursuant to which the Company divested and sold the Company's electrosurgical "Core" business segment and related intellectual property, including the Bovie® brand and trademarks, to Symmetry for gross proceeds of $97 million in cash. In connection with the Asset Purchase Agreement, the Company entered into an Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for a four-year term, whereby it will manufacture certain Core pro ducts and sell them to Symmetry at agreed upon prices. Any activity resulting from this agreement is netted and reported in the Condensed Consolidated Statements of Operations as other income (loss). Core activity for the three months ended September 30, 2021, amounted to $1.6 million with cost of sales equivalents of $1.3 million and other related expenses of $0.5 million for net other loss of $0.3 million. Core activity for the three months ended September 30, 2020, amounted to $1.8 million with cost of sales equivalents of $1.6 million and related other expenses of $0.3 million for net other loss of $0.1 million. Core activity for the nine months ended September 30, 2021 , amounted to $5.2 million with cost of sales equivalents of $4.4 million and other related expenses of $1.1 million for net other loss of $0.3 million. Core activity for the nine months ended September 30, 2020 , amounted to $6.9 million with cost of sales equivalents of $6.1 million and net other related operating expenses of $0.5 million for net other income of $0.3 million.

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours. Inventories consisted of the following: (In thousands) September 30, December 31, Raw materials $ 3,505 $ 2,243 Work in process 1,284 1,109 Finished goods 1,554 1,087 Gross inventories 6,343 4,439 Less: provision for obsolescence (303) (388) Inventories, net $ 6,040 $ 4,051

ACCRUED EXPENSES AND OTHER CURR

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	9 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consisted of the following: (in thousands) September 30, December 31, Accrued payroll $ 894 $ 808 Accrued bonuses 1,559 811 Accrued commissions 897 1,001 Accrued product warranties 547 498 Accrued product liability claim insurance deductibles 440 435 Accrued professional fees 252 222 Joint and several payroll liability 1,027 1,027 Uncertain tax positions 1,810 1,658 Sales tax payable 243 591 Other accrued expenses and current liabilities 655 227 Total accrued expenses and other current liabilities $ 8,324 $ 7,278

CHINA JOINT VENTURE

CHINA JOINT VENTURE	9 Months Ended
	Sep. 30, 2021
Noncontrolling Interest [Abstract]
CHINA JOINT VENTURE	CHINA JOINT VENTURE In 2019, the Company executed a joint venture agreement with its Chinese supplier ("China JV") whereby the Company has a 51% interest in the China JV. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately $357,000, of which approximately $203,000 and $154,000, respectively, were contributed during the three months ended June 30, 2021 and the three months ended September 30, 2020. As of the date of these condensed consolidated financial statements, the joint venture has not commenced principal operations. Changes in the Company's investment in the China JV were as follows: Three Months Ended September 30, Nine Months Ended (In thousands) 2021 2020 2021 2020 Beginning interest in China JV $ 338 $ — $ 144 $ — Contributions — 154 203 154 Net loss attributable to Apyx (13) (6) (22) (6) Ending interest in China JV $ 325 $ 148 $ 325 $ 148

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	EARNINGS (LOSS) PER SHARE Basic earnings (loss) per share (“basic EPS”) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted loss per share. Three Months Ended Nine Months Ended (in thousands, except per share data) 2021 2020 2021 2020 Numerator: Net loss attributable to stockholders $ (4,222) $ (3,728) $ (13,169) $ (10,369) Denominator: Weighted average shares outstanding - basic and diluted 34,330 34,216 34,318 34,193 Loss per share: Basic and diluted $ (0.12) $ (0.11) $ (0.38) $ (0.30) Anti-dilutive instruments excluded from diluted loss per common share: Restricted stock — 45 — 45 Options 5,534 5,028 5,534 5,028

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION Under the Company's stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, Compensation - Stock Compensation , with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize. The Company recognized approximately $1,184,000 and $3,747,000, respectively, in stock-based compensation expense during the three and nine months ended September 30, 2021, as compared with $1,063,000 and $3,209,000, respectively, for the three and nine months ended September 30, 2020. Stock option activity is summarized as follows: Number of options Weighted average exercise price Outstanding at December 31, 2020 4,938,943 $ 5.46 Granted 894,980 9.37 Exercised (109,415) 6.26 Canceled and forfeited (190,793) 8.22 Outstanding at September 30, 2021 5,533,715 $ 5.98 The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended September 30, 2021 and 2020, respectively, we received 37,049 and 16,140 options as payment in the exercise of 13,285 and 10,610 options. For the nine months ended September 30, 2021 and 2020, respectively, we received 59,104 and 29,149 options as payment in the exercise of 39,312 and 32,637 options. Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. The Company calculated the grant date fair value of options granted in 2021 ("2021 Grants") utilizing a Black Scholes model. 2021 Grants Strike price $9.29 - $11.51 Risk-free rate 0.6% - 0.8% Expected dividend yield — Expected volatility 68.9% - 70.8% Expected term (in years) 4.5 - 6

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES On March 27, 2020, the U.S. government enacted the CARES Act to provide financial relief from COVID-19. The CARES Act includes a provision that allows companies to carryback net operating losses (NOL’s) generated in the period 2018 through 2020 to prior years. In conjunction with the disposition of the Core business in 2018, the Company generated a significant amount of taxable income in 2018. Subsequently, the Company generated net losses in 2019 and 2020. For the net losses generated in 2019, the Company previously recorded a full valuation allowance on the deferred tax assets associated with its NOL carryforwards due to realization of the NOL not being probable under then existing tax law. The CARES Act makes these assets realizable and, as of the date of the CARES Act, the Company recognized an income tax benefit of approximately $3.7 million associated with the release of the valuation allowance on its Federal NOL carryforward related to 2019. For the three and nine months ended September 30, 2020, the Company also recognized income tax benefits of approximately $0.7 million and $7.1 million, respectively, related to losses before income taxes.Income tax expense (benefit) was approximately $73,000 and $(715,000) with effective tax rates of (1.8)% and 16.1% for the three months ended September 30, 2021 and 2020, respectively. Income tax expense (benefit) was approximately $246,000 and $(7,112,000) with effective tax rates of (1.9)% and 40.7% for the nine months ended September 30, 2021 and 2020, respectively. For the three and nine months ended September 30, 2021, the effective rates differ from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period, combined with interest and penalties on uncertain tax positions. For the nine months ended September 30, 2020, the effective rate differs from the statutory rate primarily due to the release of the valuation allowance on the NOL carryforward from 2019. The Company has gross unrecognized tax benefits of approximately $1,313,000 at September 30, 2021. It recognized accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes in the condensed consolidated financial statements. As of September 30, 2021, the Company had approximately $497,000 in accrued interest and penalties related to unrecognized tax benefits. Included in the income tax expense (benefit) for the three months ended September 30, 2021 and 2020, respectively, are approximately $52,000 and $43,000 of interest and penalties on the Company's uncertain tax positions. Included in the income tax expense (benefit) for the nine months ended September 30, 2021 and 2020, respectively, are approximately $152,000 and $125,000 of interest and penalties on the Company's uncertain tax positions. If the Company were to prevail on all uncertain tax positions, the resulting impact will be material as the Company will recognize approximately $1,810,000 of income tax benefits in the consolidated statement of operations. It is expected that all of the uncertain tax positions should be resolved by October 2022.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims. The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company’s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company’s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company’s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows. The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates. Purchase Commitments At September 30, 2021, the Company had purchase commitments totaling approximately $5.2 million, substantially all of which is expected to be purchased within the next twelve months.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS Several relatives of Nikolay Shilev, Apyx Bulgaria’s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev’s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev’s sister, is the manager of human resources. Svetoslav Shilev, Mr. Shilev’s son, is a quality manager in the quality assurance department. The partner in the Company's China joint venture is also a supplier to the Company. For the three months ended September 30, 2021 and 2020, the Company made purchases from this supplier of approximately $456,000 and $410,000, respectively. For the nine months ended September 30, 2021 and 2020, the Company made purchases from this supplier of approximately $1,102,000 and $1,250,000, respectively. At September 30, 2021 and December 31, 2020, respectively, the Company owed this supplier approximately $48,000 and $38,000.

GEOGRAPHIC AND SEGMENT INFORMAT

GEOGRAPHIC AND SEGMENT INFORMATION	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
GEOGRAPHIC AND SEGMENT INFORMATION	GEOGRAPHIC AND SEGMENT INFORMATION Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment. The Company's reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. "Corporate & Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred. Summarized financial information with respect to reportable segments is as follows: Three Months Ended September 30, 2021 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 10,313 $ 1,518 $ — $ 11,831 Income (loss) from operations 52 328 (4,348) (3,968) Interest income — — 2 2 Interest expense — — (3) (3) Other loss, net — — (192) (192) Income tax expense — — 73 73 Three Months Ended September 30, 2020 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 5,479 $ 1,475 $ — $ 6,954 Income (loss) from operations (1,095) 556 (3,832) (4,371) Interest income — — 10 10 Interest expense — — (25) (25) Other loss, net — — (63) (63) Income tax benefit — — (715) (715) Nine Months Ended September 30, 2021 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 27,951 $ 3,742 $ — $ 31,693 Income (loss) from operations (224) 588 (13,120) (12,756) Interest income — — 9 9 Interest expense — — (9) (9) Other loss, net — — (188) (188) Income tax expense — — 246 246 Nine Months Ended September 30, 2020 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 12,332 $ 3,915 $ — $ 16,247 Income (loss) from operations (8,371) 1,387 (11,046) (18,030) Interest income — — 233 233 Interest expense — — (39) (39) Other income, net — — 349 349 Income tax benefit — — (7,112) (7,112) International sales represented approximately 33.1% and 34.2% of total revenues for the three and nine months ended September 30, 2021, respectively, as compared with approximately 25.0% and 24.8% of total revenues for the three and nine months ended September 30, 2020, respectively. Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows: Three Months Ended Nine Months Ended (In thousands) 2021 2020 2021 2020 Sales by Domestic and International Domestic $ 7,911 $ 5,214 $ 20,860 $ 12,225 International 3,920 1,740 10,833 4,022 Total $ 11,831 $ 6,954 $ 31,693 $ 16,247

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reclassifications	Reclassifications We have reclassified certain amounts presented in the prior period to conform to the current period presentation. These reclassifications had no impact on previously reported net loss, retained earnings or net cash used in operating activities for the periods presented.
Recent Accounting Pronouncements	In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates , which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the condensed consolidated financial statements, we do not expect the impact to be material. No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.
Inventories	Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.
Share based compensation	Under the Company's stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, Compensation - Stock Compensation , with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2021
Inventory Disclosure [Abstract]
Schedule of inventory	Inventories consisted of the following: (In thousands) September 30, December 31, Raw materials $ 3,505 $ 2,243 Work in process 1,284 1,109 Finished goods 1,554 1,087 Gross inventories 6,343 4,439 Less: provision for obsolescence (303) (388) Inventories, net $ 6,040 $ 4,051

ACCRUED EXPENSES AND OTHER CU_2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	Accrued expenses and other current liabilities consisted of the following: (in thousands) September 30, December 31, Accrued payroll $ 894 $ 808 Accrued bonuses 1,559 811 Accrued commissions 897 1,001 Accrued product warranties 547 498 Accrued product liability claim insurance deductibles 440 435 Accrued professional fees 252 222 Joint and several payroll liability 1,027 1,027 Uncertain tax positions 1,810 1,658 Sales tax payable 243 591 Other accrued expenses and current liabilities 655 227 Total accrued expenses and other current liabilities $ 8,324 $ 7,278

CHINA JOINT VENTURE (Tables)

CHINA JOINT VENTURE (Tables)	9 Months Ended
	Sep. 30, 2021
Noncontrolling Interest [Abstract]
Schedule of China Joint Venture	Changes in the Company's investment in the China JV were as follows: Three Months Ended September 30, Nine Months Ended (In thousands) 2021 2020 2021 2020 Beginning interest in China JV $ 338 $ — $ 144 $ — Contributions — 154 203 154 Net loss attributable to Apyx (13) (6) (22) (6) Ending interest in China JV $ 325 $ 148 $ 325 $ 148

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Basic and diluted earnings (loss) per share	The following table provides the computation of basic and diluted loss per share. Three Months Ended Nine Months Ended (in thousands, except per share data) 2021 2020 2021 2020 Numerator: Net loss attributable to stockholders $ (4,222) $ (3,728) $ (13,169) $ (10,369) Denominator: Weighted average shares outstanding - basic and diluted 34,330 34,216 34,318 34,193 Loss per share: Basic and diluted $ (0.12) $ (0.11) $ (0.38) $ (0.30) Anti-dilutive instruments excluded from diluted loss per common share: Restricted stock — 45 — 45 Options 5,534 5,028 5,534 5,028

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2021
Share-based Payment Arrangement [Abstract]
Summary of stock options and stock awards	Stock option activity is summarized as follows: Number of options Weighted average exercise price Outstanding at December 31, 2020 4,938,943 $ 5.46 Granted 894,980 9.37 Exercised (109,415) 6.26 Canceled and forfeited (190,793) 8.22 Outstanding at September 30, 2021 5,533,715 $ 5.98
Schedule of option fair value assumptions	The Company calculated the grant date fair value of options granted in 2021 ("2021 Grants") utilizing a Black Scholes model. 2021 Grants Strike price $9.29 - $11.51 Risk-free rate 0.6% - 0.8% Expected dividend yield — Expected volatility 68.9% - 70.8% Expected term (in years) 4.5 - 6

GEOGRAPHIC AND SEGMENT INFORM_2

GEOGRAPHIC AND SEGMENT INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
Schedule of reporting information by segment	Summarized financial information with respect to reportable segments is as follows: Three Months Ended September 30, 2021 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 10,313 $ 1,518 $ — $ 11,831 Income (loss) from operations 52 328 (4,348) (3,968) Interest income — — 2 2 Interest expense — — (3) (3) Other loss, net — — (192) (192) Income tax expense — — 73 73 Three Months Ended September 30, 2020 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 5,479 $ 1,475 $ — $ 6,954 Income (loss) from operations (1,095) 556 (3,832) (4,371) Interest income — — 10 10 Interest expense — — (25) (25) Other loss, net — — (63) (63) Income tax benefit — — (715) (715) Nine Months Ended September 30, 2021 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 27,951 $ 3,742 $ — $ 31,693 Income (loss) from operations (224) 588 (13,120) (12,756) Interest income — — 9 9 Interest expense — — (9) (9) Other loss, net — — (188) (188) Income tax expense — — 246 246 Nine Months Ended September 30, 2020 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 12,332 $ 3,915 $ — $ 16,247 Income (loss) from operations (8,371) 1,387 (11,046) (18,030) Interest income — — 233 233 Interest expense — — (39) (39) Other income, net — — 349 349 Income tax benefit — — (7,112) (7,112)
Schedule of revenue by geographic area	Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows: Three Months Ended Nine Months Ended (In thousands) 2021 2020 2021 2020 Sales by Domestic and International Domestic $ 7,911 $ 5,214 $ 20,860 $ 12,225 International 3,920 1,740 10,833 4,022 Total $ 11,831 $ 6,954 $ 31,693 $ 16,247

DISPOSAL OF BUSINESS (Details)

DISPOSAL OF BUSINESS (Details) - USD ($) $ in Millions	Aug. 30, 2018	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from the disposition of Core business	$ 97
Symmetry Surgical Inc. | Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Asset purchase agreement, term	4 years
Sales		$ 1.6	$ 1.8	$ 5.2	$ 6.9
Cost of sales		1.3	1.6	4.4	6.1
Operating expenses		0.5	0.3	1.1	0.5
Net other income (loss)		$ (0.3)	$ (0.1)	$ (0.3)	$ 0.3

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 3,505	$ 2,243
Work in process	1,284	1,109
Finished goods	1,554	1,087
Gross inventories	6,343	4,439
Less: provision for obsolescence	(303)	(388)
Inventories, net	$ 6,040	$ 4,051

ACCRUED EXPENSES AND OTHER CU_3

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Accrued payroll	$ 894	$ 808
Accrued bonuses	1,559	811
Accrued commissions	897	1,001
Accrued product warranties	547	498
Accrued product liability claim insurance deductibles	440	435
Accrued professional fees	252	222
Joint and several payroll liability	1,027	1,027
Uncertain tax positions	1,810	1,658
Sales tax payable	243	591
Other accrued expenses and current liabilities	655	227
Total accrued expenses and other current liabilities	$ 8,324	$ 7,278

CHINA JOINT VENTURE - Narrative

CHINA JOINT VENTURE - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2019
Noncontrolling Interest [Line Items]
Required capital contribution						$ 357
Contributions from non-controlling interest			$ 148	$ 195	$ 148
Chinese Supplier
Noncontrolling Interest [Line Items]
Ownership interest						51.00%
Corporate Joint Venture
Noncontrolling Interest [Line Items]
Contributions from non-controlling interest	$ 0	$ 203	$ 154	$ 203	$ 154

CHINA JOINT VENTURE - Rollforwa

CHINA JOINT VENTURE - Rollforward of Joint Venture (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning interest in China JV				$ 138
Contributions			$ 148	195	$ 148
Net loss attributable to Apyx	$ (12)		(6)	(21)	(6)
Ending interest in China JV	312			312
Corporate Joint Venture
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning interest in China JV	338		0	144	0
Contributions	0	$ 203	154	203	154
Net loss attributable to Apyx	(13)		(6)	(22)	(6)
Ending interest in China JV	$ 325	$ 338	$ 148	$ 325	$ 148

EARNINGS (LOSS) PER SHARE (Deta

EARNINGS (LOSS) PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share Reconciliation [Abstract]
Net loss attributable to stockholders, basic	$ (4,222)	$ (3,728)	$ (13,169)	$ (10,369)
Net loss attributable to stockholders, diluted	$ (4,222)	$ (3,728)	$ (13,169)	$ (10,369)
Denominator:
Weighted average shares outstanding - basic (in shares)	34,330	34,216	34,318	34,193
Weighted average shares outstanding - diluted (in shares)	34,330	34,216	34,318	34,193
Loss per share:
Basic (in dollars per share)	$ (0.12)	$ (0.11)	$ (0.38)	$ (0.30)
Diluted (in dollars per share)	$ (0.12)	$ (0.11)	$ (0.38)	$ (0.30)
Restricted stock
Anti-dilutive instruments excluded from diluted loss per common share:
Anti-dilutive instruments (in shares)	0	45	0	45
Options
Anti-dilutive instruments excluded from diluted loss per common share:
Anti-dilutive instruments (in shares)	5,534	5,028	5,534	5,028

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock based compensation	$ 1,184	$ 1,063	$ 3,747	$ 3,209
Stock swaps equity instruments received (in shares)	37,049	16,140	59,104	29,149
Stock swaps (in shares)	13,285	10,610	39,312	32,637

STOCK-BASED COMPENSATION - Summ

STOCK-BASED COMPENSATION - Summary of Stock Options (Details)	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Number of options
Outstanding, beginning of period (in shares) | shares	4,938,943
Granted (in shares) | shares	894,980
Exercised (in shares) | shares	(109,415)
Canceled and forfeited (in shares) | shares	(190,793)
Outstanding, end of period (in shares) | shares	5,533,715
Weighted average exercise price
Outstanding, beginning of period (in dollars per share) | $ / shares	$ 5.46
Granted (in dollars per share) | $ / shares	9.37
Exercised (in dollars per share) | $ / shares	6.26
Canceled and forfeited (in dollars per shares) | $ / shares	8.22
Outstanding, end of period (in dollars per share) | $ / shares	$ 5.98

STOCK-BASED COMPENSATION - Fair

STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)	9 Months Ended
	Sep. 30, 2021$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Strike price (in dollars per share)	$ 9.37
Expected dividend yield	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Strike price (in dollars per share)	$ 9.29
Risk-free rate	0.60%
Expected volatility	68.90%
Expected term (in years)	4 years 6 months
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Strike price (in dollars per share)	$ 11.51
Risk-free rate	0.80%
Expected volatility	70.80%
Expected term (in years)	6 years

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Release of valuation allowance					$ 3,700
Income tax expense (benefit)	$ 73	$ (715)	$ 246	$ (7,112)
Effective income tax rate	(1.80%)	16.10%	(1.90%)	40.70%
Unrecognized tax benefits	$ 1,313		$ 1,313
Accrued interest and penalties	497		497
Interest and penalties included in income tax expense	52	$ 43	152	$ 125
Uncertain tax positions that would impact effective tax rate	$ 1,810		$ 1,810

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Narrative (Details) $ in Millions	Sep. 30, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
Purchase obligation	$ 5.2

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - Co-venturer - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Related Party Transaction [Line Items]
Purchases from related party	$ 456	$ 410	$ 1,102	$ 1,250
Due to related parties	$ 48		$ 48		$ 38

GEOGRAPHIC AND SEGMENT INFORM_3

GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details) - segment	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting [Abstract]
Number of reportable segments			2
Number of operating segments			2
International sales, percent of total revenue	33.10%	25.00%	34.20%	24.80%

GEOGRAPHIC AND SEGMENT INFORM_4

GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
Sales	$ 11,831	$ 6,954	$ 31,693	$ 16,247
Income (loss) from operations	(3,968)	(4,371)	(12,756)	(18,030)
Interest income	2	10	9	233
Interest expense	(3)	(25)	(9)	(39)
Other income (loss), net	(192)	(63)	(188)	349
Income tax (benefit) expense	73	(715)	246	(7,112)
Operating Segments | Advanced Energy
Segment Reporting Information [Line Items]
Sales	10,313	5,479	27,951	12,332
Income (loss) from operations	52	(1,095)	(224)	(8,371)
Interest income	0	0	0	0
Interest expense	0	0	0	0
Other income (loss), net	0	0	0	0
Income tax (benefit) expense	0	0	0	0
Operating Segments | OEM
Segment Reporting Information [Line Items]
Sales	1,518	1,475	3,742	3,915
Income (loss) from operations	328	556	588	1,387
Interest income	0	0	0	0
Interest expense	0	0	0	0
Other income (loss), net	0	0	0	0
Income tax (benefit) expense	0	0	0	0
Corporate & Other
Segment Reporting Information [Line Items]
Sales	0	0	0	0
Income (loss) from operations	(4,348)	(3,832)	(13,120)	(11,046)
Interest income	2	10	9	233
Interest expense	(3)	(25)	(9)	(39)
Other income (loss), net	(192)	(63)	(188)	349
Income tax (benefit) expense	$ 73	$ (715)	$ 246	$ (7,112)

GEOGRAPHIC AND SEGMENT INFORM_5

GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
Sales	$ 11,831	$ 6,954	$ 31,693	$ 16,247
Domestic
Segment Reporting Information [Line Items]
Sales	7,911	5,214	20,860	12,225
International
Segment Reporting Information [Line Items]
Sales	$ 3,920	$ 1,740	$ 10,833	$ 4,022